Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s

Comparative study of antitumor activity of cisplatin and dioxadet in chemoperfusion treatment was carried out on ascitic ovarian cancer model in 172 Vistar female rats. Ovarian cancer was inoculated intraperitoneally at a volume of 0.5 ml per rat with concentration of tumor cells 2×107 / ml. The dru...

Full description

Bibliographic Details
Main Authors: V. G. Bespalov, О. А. Belyaeva, G. S. Kireeva, K. Yu. Senchik, A. N. Stukov, A. M. Belyaev
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2016-02-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/25
_version_ 1797875929519751168
author V. G. Bespalov
О. А. Belyaeva
G. S. Kireeva
K. Yu. Senchik
A. N. Stukov
A. M. Belyaev
author_facet V. G. Bespalov
О. А. Belyaeva
G. S. Kireeva
K. Yu. Senchik
A. N. Stukov
A. M. Belyaev
author_sort V. G. Bespalov
collection DOAJ
description Comparative study of antitumor activity of cisplatin and dioxadet in chemoperfusion treatment was carried out on ascitic ovarian cancer model in 172 Vistar female rats. Ovarian cancer was inoculated intraperitoneally at a volume of 0.5 ml per rat with concentration of tumor cells 2×107 / ml. The drugs were administered once in 48 hours after inoculation of ovarian cancer in maximum tolerated doses (MTD). Normothermic intraperitoneal chemoperfusion (IPEC) and hyperthermic intraperitoneal chemoperfusion (HIPEC) were performed with cisplatin or dioxadet at doses that were 5−20 times higher than those for their standard intraperitoneal administration. Antitumor effects of the drugs were estimated in increase of median survival time (MST). In case of IPEC and HIPEC cisplatin increased the MST by 317  % and 183  % (р<0.05) respectively, when dioxadet increased the MST by 244  % and 444  % (р<0.05) respectively compared to the control group of animals that didn’t receive any treatment. HIPEC with dioxadet is the most effective regimen in experimental treatment of advanced ovarian cancer.
first_indexed 2024-04-10T01:55:14Z
format Article
id doaj.art-5656324caaeb44bba63155cac21ef96a
institution Directory Open Access Journal
issn 1814-4861
2312-3168
language Russian
last_indexed 2024-04-10T01:55:14Z
publishDate 2016-02-01
publisher Russian Academy of Sciences, Tomsk National Research Medical Center
record_format Article
series Сибирский онкологический журнал
spelling doaj.art-5656324caaeb44bba63155cac21ef96a2023-03-13T09:05:46ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-02-0102141825Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental sV. G. Bespalov0О. А. Belyaeva1G. S. Kireeva2K. Yu. Senchik3A. N. Stukov4A. M. Belyaev5ФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-ПетербургФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-ПетербургФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-ПетербургФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-ПетербургФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-ПетербургФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-ПетербургComparative study of antitumor activity of cisplatin and dioxadet in chemoperfusion treatment was carried out on ascitic ovarian cancer model in 172 Vistar female rats. Ovarian cancer was inoculated intraperitoneally at a volume of 0.5 ml per rat with concentration of tumor cells 2×107 / ml. The drugs were administered once in 48 hours after inoculation of ovarian cancer in maximum tolerated doses (MTD). Normothermic intraperitoneal chemoperfusion (IPEC) and hyperthermic intraperitoneal chemoperfusion (HIPEC) were performed with cisplatin or dioxadet at doses that were 5−20 times higher than those for their standard intraperitoneal administration. Antitumor effects of the drugs were estimated in increase of median survival time (MST). In case of IPEC and HIPEC cisplatin increased the MST by 317  % and 183  % (р<0.05) respectively, when dioxadet increased the MST by 244  % and 444  % (р<0.05) respectively compared to the control group of animals that didn’t receive any treatment. HIPEC with dioxadet is the most effective regimen in experimental treatment of advanced ovarian cancer.https://www.siboncoj.ru/jour/article/view/25нормо- и гипертермическая интраперитонеальная химиоперфузияопухоль яичниковдиоксадэтцисплатин
spellingShingle V. G. Bespalov
О. А. Belyaeva
G. S. Kireeva
K. Yu. Senchik
A. N. Stukov
A. M. Belyaev
Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
Сибирский онкологический журнал
нормо- и гипертермическая интраперитонеальная химиоперфузия
опухоль яичников
диоксадэт
цисплатин
title Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
title_full Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
title_fullStr Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
title_full_unstemmed Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
title_short Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
title_sort intraperitoneal chemoperfusion treatment of advanced ovarian cancer with dioxadet compared to cisplatin in experimental s
topic нормо- и гипертермическая интраперитонеальная химиоперфузия
опухоль яичников
диоксадэт
цисплатин
url https://www.siboncoj.ru/jour/article/view/25
work_keys_str_mv AT vgbespalov intraperitonealchemoperfusiontreatmentofadvancedovariancancerwithdioxadetcomparedtocisplatininexperimentals
AT oabelyaeva intraperitonealchemoperfusiontreatmentofadvancedovariancancerwithdioxadetcomparedtocisplatininexperimentals
AT gskireeva intraperitonealchemoperfusiontreatmentofadvancedovariancancerwithdioxadetcomparedtocisplatininexperimentals
AT kyusenchik intraperitonealchemoperfusiontreatmentofadvancedovariancancerwithdioxadetcomparedtocisplatininexperimentals
AT anstukov intraperitonealchemoperfusiontreatmentofadvancedovariancancerwithdioxadetcomparedtocisplatininexperimentals
AT ambelyaev intraperitonealchemoperfusiontreatmentofadvancedovariancancerwithdioxadetcomparedtocisplatininexperimentals